This is to provide you with important information regarding Dextran 40 (10% LMD in 5% Dextrose Injection), which is indicated to enhance blood flow, particularly in the microcirculation, and is manufactured by Hospira Inc., a Pfizer company.

Based upon FDA’s evaluation of stability data, FDA has extended the expiration dates on two lots of 10% LMD in 5% Dextrose (#09141JT and #12090JT) in 500 mL bags for 8 months beyond their expiry dates, as follows:

#09141JT: from September 1, 2021, to May 1, 2022, and
#12090JT: from December 1, 2021, to August 1, 2022.

The FDA is not requiring or recommending that the lots identified above be relabeled with new expiration dates. If you have bags of lot #09141JT in your current inventory, labeled with an expiration date of September 1, 2021, you may continue to maintain the product in your inventory and keep it available for use until May 1, 2022. If you have bags of lot #12090JT in your current inventory, labeled with an expiration date of December 1, 2021, you may continue to maintain the product in your inventory and keep it available for use until August 1, 2022.

Please use available inventory on a first-in, first-out basis through the new expiration dates as noted above.